---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-060802"
form_type: "8-K/A"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:32:52.914265+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Galera completes acquisition of Nova Pharmaceuticals, files 8-K/A with SEC waiver for financial statements

## Summary
- Acquisition of Nova Pharmaceuticals closed on Dec 30, 2024, via merger agreement.
- SEC granted waiver from Rule 3-05 and Article 11, allowing omission of audited FY2023 and unaudited interim financials for 9 months ended Sep 30, 2023/2024.
- Pro forma financial information also omitted under the waiver.
- No deal value or terms disclosed in this filing; full financial impact not provided to investors.

## SEC filing metadata
- accession: 0001193125-25-060802
- form_type: 8-K/A
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312525060802/0001193125-25-060802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312525060802/d928346d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-060802
- JSON: https://secwatch.observer/filing/0001193125-25-060802.json
- Plain text: https://secwatch.observer/filing/0001193125-25-060802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.